[{"id":"31cd42bd-2aac-4afa-811c-51661bcc2afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411679","created_at":"2022-06-09T13:55:28.993Z","updated_at":"2024-07-02T16:35:45.971Z","phase":"Phase 2","brief_title":"EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer","source_id_and_acronym":"NCT05411679","lead_sponsor":"Ellipses Pharma","biomarkers":" PD-L1 • ATM","pipe":" | ","alterations":" ATM expression","tags":["PD-L1 • ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • davamotecan pegadexamer (EP0057)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-06-12"},{"id":"407fb800-d7d6-4bbe-b0d0-7708d8e4c6fc","acronym":"ATM","url":"https://clinicaltrials.gov/study/NCT04976803","created_at":"2021-07-26T17:53:26.019Z","updated_at":"2024-07-02T16:36:06.294Z","phase":"","brief_title":"Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein","source_id_and_acronym":"NCT04976803 - ATM","lead_sponsor":"Artios Pharma Ltd","biomarkers":" ATM • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation • ATM expression","tags":["ATM • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation • ATM expression"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 05/28/2021","start_date":" 05/28/2021","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-08-01"},{"id":"5d48ca1c-897a-41c8-9170-c90e8cff5ce0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780608","created_at":"2021-01-18T18:41:55.942Z","updated_at":"2024-07-02T16:36:08.720Z","phase":"Phase 2","brief_title":"This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)","source_id_and_acronym":"NCT03780608","lead_sponsor":"Samsung Medical Center","biomarkers":" ATM","pipe":" | ","alterations":" ATM expression","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-15"},{"id":"b779fc61-9ce2-46a0-bf31-8408e99ed716","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010096","created_at":"2021-08-18T15:53:42.006Z","updated_at":"2024-07-02T16:36:09.743Z","phase":"Phase 1b","brief_title":"BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05010096","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • BRCA1 • BRCA2 • PTEN • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" PIK3CA mutation • ATM mutation • PTEN mutation • ATM deletion • ATM expression","tags":["PIK3CA • BRCA1 • BRCA2 • PTEN • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ATM mutation • PTEN mutation • ATM deletion • ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib) • elimusertib (BAY 1895344)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 03/22/2022","primary_completion_date":" 03/22/2022","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2022-05-27"},{"id":"b1d76806-e319-4f41-99b1-2eaf6dccd326","acronym":"IMOX","url":"https://clinicaltrials.gov/study/NCT03473327","created_at":"2021-01-18T17:06:57.634Z","updated_at":"2024-07-02T16:37:12.882Z","phase":"","brief_title":"Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery","source_id_and_acronym":"NCT03473327 - IMOX","lead_sponsor":"Zealand University Hospital","biomarkers":" TP53 • IL6 • TNFA • IL2 • IL10 • TGFB1 • FOXO3 • IL1B • ISG20","pipe":" | ","alterations":" ATM expression","tags":["TP53 • IL6 • TNFA • IL2 • IL10 • TGFB1 • FOXO3 • IL1B • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM expression"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-03-22"},{"id":"43e10b1a-f6dd-4102-b559-116081ca41ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02940132","created_at":"2021-01-17T17:55:31.388Z","updated_at":"2024-07-02T16:37:15.762Z","phase":"Phase 1","brief_title":"A Study of SC10914 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02940132","lead_sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","biomarkers":" BRCA1 • BRCA2 • ATM","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 expression • ATM expression","tags":["BRCA1 • BRCA2 • ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 expression • ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SC10914"],"overall_status":"Unknown status","enrollment":" Enrollment 72","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2017-12-06"}]